Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Combination Chemotherapy in Treating Women With Resected Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Registration Number
- NCT00033683
- Locations
- 🇬🇧
St. Georges Hospital Medical School, London, England, United Kingdom
🇬🇧Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧Leicester Royal Infirmary, Leicester, England, United Kingdom
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-08-13
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00004081
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Registration Number
- NCT00004873
- Locations
- 🇨🇭
Hopital Cantonal Universitaire de Geneva, Geneva, Switzerland
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00042835
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 95
- Registration Number
- NCT00015938
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00049088
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 27
- Registration Number
- NCT00025493
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00040807
- Locations
- 🇺🇸
Penrose Cancer Center, Colorado Springs, Colorado, United States
🇺🇸Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Genta Incorporated
- Registration Number
- NCT00030641
- Locations
- 🇺🇸
Augusta Oncology Associates, Augusta, Georgia, United States
🇺🇸Harold Simmons Cancer Center, Dallas, Texas, United States
🇺🇸West Virginia University Hospitals, Morgantown, West Virginia, United States
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 770
- Registration Number
- NCT00004001
- Locations
- 🇺🇸
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.